>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

MIND +21.7%, (light volume), BABA +12.8%, (guidance at Investor Day) OKTA +7.1%, AGX +4.1%, ONVO +3.9%, SJM +3.1%, NEPT +2.7%, VRNT +2%, FCEL +1.9%, ABM +1.7%, (also SVP/President of ABM Technical Solutions Scott Giacobbe elected EVP and will succeed James McClure as EVP/COO effective November 1 2017)

M&A news:

SCLN +8.4% (Buyer Consortium will acquire all the outstanding shares of SciClone for $11.18/share in cash)
VRX +2.7% (to sell its iNova Pharmaceuticals business to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group (CG) for $930 mln in cash)
FOR +0.9% (determines that DHI's proposal to acquire the co for $16.25 'could reasonably be expected to lead to a Superior Proposal)
P +0.2% (Sirius XM Radio (SIRI) in talks to make an investment in Pandora after outright acquisition talks are said to have ended without a deal, according to Reuters)

Select China/BABA peers and related names showing strength following BABA's guidance at Investor Day:

BZUN +10.8%, YHOO +9.7%, JD +4.8%, MOMO +3.1%, BIDU +2.4%, WB +2.1%, SINA +1.7%

Other news:

INSG +37.8% (Inseego terminates TCL transaction to sell MiFi business, plans to restructure, changes leadership, details improved profitability outlook; will call at 8:30am ET on June 8 )
NXTD +17.5% (announces its Token Service Provider solution has been successfully integrated with the Visa Token Service and is now qualified as a Visa TR-TSP partner through the Visa Ready Program)
DRWI +17.1% (seeing continued strength; also Nasdaq Hearings Panel granted the Company's request for continued listing)
VSTM +14.6% (will present long-term follow-up data from the DYNAMO study at the ICML)
COOL +11.7% (announces pre-clinical results demonstrating that its lead product, SkinTE)
ONCS +7.5% (granted orphan designation by the FDA for DNA Plasmid Vector encoding IL-12)
MOSY +5.4% (continued strength following 125% move y'day)
CASC +5% (confirms the FDA granted orphan designation to tucatinib for the treatment of breast cancer patients with brain metastases)
AMD +3.8% (continued strength)
CVNA +2.7% (extending earnings related move higher)
INO +2.7% (commences its phase 3 clinical program to evaluate the efficacy of VGX-3100 to treat cervical dysplasia caused by HPV after FDA removes clinical hold)
SSTI +1.8% (IPO seeing continued strength)
RGNX +1.3% (AveXis and REGENXBIO announce an exclusive worldwide license agreement for AveXis)
TPX +1.2% (10% owner H Partners disclosed the purchase of 100K shares)

Analyst comments: